Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

New tools for assessing the individual risk of metastasis in renal cell carcinoma.

Herrmann E, Weishaupt C, Pöppelmann B, Hillgruber C, Pühse G, Krabbe LM, Feld M, Steinhoff M, Goerge T.

Clin Exp Metastasis. 2013 Feb;30(2):215-24. doi: 10.1007/s10585-012-9529-6. Epub 2012 Aug 23.

PMID:
22915161
2.

Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.

Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS.

Am J Surg Pathol. 1997 Jun;21(6):621-35.

PMID:
9199639
3.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

4.

Characterization of primary renal carcinoma cultures.

Sievers E, Dreimuller P, Haferkamp A, Schmidt-Wolf IG, Buchler MW, Schmidt J, Marten A.

Urol Int. 2007;79(3):235-43.

PMID:
17940356
5.

Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.

Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F.

Tissue Antigens. 2006 Oct;68(4):303-10.

PMID:
17026465
6.

Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis.

Buchner A, Castro M, Hennig A, Popp T, Assmann G, Stief CG, Zimmermann W.

Urology. 2010 Aug;76(2):507.e6-11. doi: 10.1016/j.urology.2010.03.042. Epub 2010 Jun 9.

PMID:
20538322
7.
8.

Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay.

Mandic R, Ludwig T, Oberleithner H, Werner JA.

Clin Exp Metastasis. 2004;21(8):699-704.

PMID:
16035614
9.

GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.

Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30.

10.

Prognostic factors in renal cell carcinoma.

Volpe A, Patard JJ.

World J Urol. 2010 Jun;28(3):319-27. doi: 10.1007/s00345-010-0540-8. Epub 2010 Apr 3. Review.

PMID:
20364259
11.

Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A.

Desch A, Strozyk EA, Bauer AT, Huck V, Niemeyer V, Wieland T, Schneider SW.

Am J Pathol. 2012 Aug;181(2):693-705. doi: 10.1016/j.ajpath.2012.04.012. Epub 2012 May 31.

PMID:
22659470
13.

Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.

Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B.

Scand J Urol Nephrol. 2007;41(1):5-9.

PMID:
17366095
14.

Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.

Ohno Y, Izumi M, Yoshioka K, Ohori M, Yonou H, Tachibana M.

Oncol Rep. 2008 Sep;20(3):511-6.

PMID:
18695899
15.

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.

Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ.

Cancer. 2003 Oct 15;98(8):1611-9.

16.

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900. doi: 10.1158/1055-9965.EPI-08-0786. Epub 2009 Feb 24.

17.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

18.

Metastatic renal cell carcinoma to the bladder: a clinicopathologic and immunohistochemical study.

Sim SJ, Ro JY, Ordonez NG, Park YW, Kee KH, Ayala AG.

Mod Pathol. 1999 Apr;12(4):351-5.

PMID:
10229498
19.

Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.

Harada K, Miyake H, Kusuda Y, Fujisawa M.

BJU Int. 2012 Dec;110(11 Pt C):E1131-7. doi: 10.1111/j.1464-410X.2012.11297.x. Epub 2012 Jun 19.

20.

Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.

Lee CT, Genega EM, Hutchinson B, Fearn PA, Kattan MW, Russo P, Reuter VE.

Urol Oncol. 2003 May-Jun;21(3):179-84.

PMID:
12810203

Supplemental Content

Support Center